|
Presentations in this session:16:30
WESS201
Abstract | Antiviral effects and tolerability of the CCR5 monoclonal antibody PRO 140: a proof of concept study in HIV-infected individuals
Presented by W.C. Olson
Saag M.S.1, Jacobson J.M.2, Thompson M.3, Fischl M.4, Liporace R.5, Reichman R.C.6, Redfield R.R.7, Fichtenbaum C.J.8, Zingman B.S.9, Patel M.C.10, D'Ambrosio P.11, Michael M.11, Kroger H.11, Ly H.11, Rotshteyn Y.11, Stavola J.J.11, Maddon P.J.11, Kremer A.B.11, Olson W.C.11
1University of Alabama, UAB Center for AIDS Research, Birmingham, United States, 2Drexel University, Philadelphia, United States, 3AIDS Research Consortium of Atlanta, Atlanta, United States, 4University of Miami, Miami, United States, 5Albany Medical Center, Albany, United States, 6University of Rochester, Rochester, United States, 7University of Maryland, Baltimore, United States, 8University of Cincinnati, Cincinnati, United States, 9Montefiore Medical Center and the Einstein/Montefiore Center for AIDS Research, Bronx, United States, 10Jacobi Medical Center, Bronx, United States, 11Progenics Pharmaceuticals, Inc., Tarrytown, United States
| 16:45
WESS202
Abstract | Short-term monotherapy with UK-453,061, a novel NNRTI, reduces viral load in HIV infected patients
Presented by Tim Jenkins
Fätkenheuer G.1, Staszewski S.2, Plettenburg A.3, Hackman F.4, Layton G.4, McFadyen L.4, Davis J.4, Jenkins T.4
1Cologne University, Cologne, Germany, 2JH Goethe University, Frankfurt, Germany, 3Institute for Interdisciplinary Infectiology, Hamburg, Germany, 4Pfizer Global R & D, Sandwich, United Kingdom
| 17:00
WESS203
Abstract | Superior activity of apricitabine compared to 3TC over 21 days in treatment experienced HIV-1 infected patients failing therapy with M184V and NRTI resistance
Presented by Pedro Cahn, Argentina
Cahn P.1, Altclas J.2, Martins M.3, Losso M.4, Cassetti I.5, Cooper D.6
1Fundacion Huesped, Buenos Aires, Argentina, 2Sanatorio de la Trinidad Mitre, Buenos Aires, Argentina, 3Instituto Oulton, Cordoba, Argentina, 4Hospital J M Ramos Mejia, Buenos Aires, Argentina, 5Helios Salud, Buenos Aires, Argentina, 6St Vincent's Hospital Medical Centre, Sydney, Australia
| 17:15
WESS204-1
Abstract | DUET-1: 24 week results of a phase III randomised double-blind trial to evaluate the efficacy and safety of TMC125 versus placebo in 612 treatment-experienced HIV-1 infected patients
Presented by Anthony Mills
Mills A.1, Cahn P.2, Grinsztejn B.3, Haubrich R.4, Lalezari J.5, Madruga J.V.6, Pialoux G.7, Wilkin T.8, Peeters M.9, Vingerhoets J.9, De Smedt G.9, Leopold L.10, Trefiglio R.10, Woodfall B.9, on behalf of the DUET-1 study group
1Private Practice, Beverly Hills, United States, 2Hospital Juan A. Fernández and Fundación Huesped, Buenos Aires, Argentina, 3Instituto de Pesquisa Clinica Evandro Chagas-Fiocruz, Rio de Janeiro, Brazil, 4University of California San Diego, San Diego, United States, 5Quest Clinical Research, San Francisco, United States, 6Centro de Referência e Treinamento DST/AIDS, São Paulo, Brazil, 7Service des Maladies Infectieuses, APHP, Hôpital Tenon, Paris, France, 8Weill Medical College of Cornell University, New York, United States, 9Tibotec BVBA, Mechelen, Belgium, 10Tibotec Inc, Yardley, United States
| 17:23
WESS204-2
Abstract | DUET-2: 24 week results of a phase III randomised double-blind trial to evaluate the efficacy and safety of TMC125 versus placebo in 591 treatment-experienced HIV-1 infected patients
Presented by Christine Katlama, France
Katlama C.1, Campbell T.2, Clotet B.3, Johnson M.4, Lazzarin A.5, Arasteh K.6, Towner W.7, Trottier B.8, Peeters M.9, Vingerhoets J.9, De Smedt G.9, Baeten B.9, Beets G.9, Sinha R.9, Woodfall B.9, on behalf of the DUET-2 study group
1Hôpital Pitié-Salpêtrière, Paris, France, 2University of Colorado Health Sciences Center, Denver, United States, 3Hospital Universitari Germans Trias i Pujol and irsiCaixa Foundation, UAB, Barcelona, Catalonia, Spain, 4Royal Free Hospital, London, United Kingdom, 5Vita-Salute, San Raffaele University, Milan, Italy, 6Epimed, c/o Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany, 7Kaiser Permanente, Los Angeles, CA, United States, 8Clinique Médicale l'Actuel, Montréal, Quebec, Canada, 9Tibotec BVBA, Mechelen, Belgium
|
|